ALEXION PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)
- First Posted Date
- 2008-08-21
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT00739505
- Locations
- 🇺🇸
Barnes Jewish Hospital- Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇨🇦Department of Pediatrics & Child Health, Health Sciences Centre Winnipeg, University of Manitoba, Winnipeg, Manitoba, Canada
Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT00727194
- Locations
- 🇺🇸
University of California, Irvine, Orange, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT00675844
- Locations
- 🇺🇸
Clinical Trial Site, Dallas, Texas, United States
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
- Conditions
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00648739
Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma
- Conditions
- First Posted Date
- 2007-06-13
- Last Posted Date
- 2009-01-15
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT00485576
- Locations
- 🇨🇦
Hospital Laval, Ste-Foy, Quebec, Canada
🇨🇦McMaster University, Hamilton, Ontario, Canada
The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol
- Conditions
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2014-05-06
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT00438789
- Locations
- 🇺🇸
Anthony Botti, Livingston, New Jersey, United States
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection
- Conditions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00401947
- Locations
- 🇳🇱
Clinical Trial Site, Utrecht, Netherlands
Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A
- Conditions
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT00380159
- Locations
- 🇪🇸
Clinical Trial Site, Madrid, Spain
Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants
- Conditions
- Interventions
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT00350272
- Locations
- 🇵🇷
Clinical Trial Site, San Juan, Puerto Rico
Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation
- First Posted Date
- 2006-04-07
- Last Posted Date
- 2023-08-25
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT00312039
- Locations
- 🇺🇸
Clinical Trial Site, Cincinnati, Ohio, United States